Shares of Cempra Inc. (NASDAQ:CEMP) saw strong trading volume on Tuesday . 651,226 shares were traded during trading, a decline of 1% from the previous session’s volume of 657,737 shares.The stock last traded at $18.93 and had previously closed at $18.06.

Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Cempra in a research report on Tuesday. They set an “overweight” rating and a $31.00 target price for the company. WBB Securities reissued a “buy” rating and set a $40.00 target price on shares of Cempra in a research report on Tuesday, July 5th. Cowen and Company reissued a “buy” rating on shares of Cempra in a research report on Friday, June 24th. Needham & Company LLC reissued a “buy” rating and set a $48.00 target price on shares of Cempra in a research report on Friday, June 24th. Finally, Stifel Nicolaus decreased their target price on shares of Cempra from $51.00 to $47.00 and set a “buy” rating for the company in a research report on Friday, June 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. Cempra currently has an average rating of “Buy” and an average price target of $36.27.

The company’s market capitalization is $910.02 million. The firm’s 50-day moving average price is $18.13 and its 200-day moving average price is $18.26.

Cempra (NASDAQ:CEMP) last issued its quarterly earnings results on Monday, May 2nd. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.02. During the same period last year, the business earned ($0.41) earnings per share. The business had revenue of $2.70 million for the quarter, compared to analysts’ expectations of $3.94 million. The company’s revenue was down 80.7% on a year-over-year basis. On average, analysts anticipate that Cempra Inc. will post ($2.54) earnings per share for the current fiscal year.

A number of hedge funds and institutional investors have modified their holdings of CEMP. Sei Investments Co. boosted its position in shares of Cempra by 717.8% in the fourth quarter. Sei Investments Co. now owns 110,192 shares of the company’s stock worth $3,431,000 after buying an additional 96,718 shares during the period. California Public Employees Retirement System boosted its position in shares of Cempra by 427.9% in the fourth quarter. California Public Employees Retirement System now owns 117,200 shares of the company’s stock valued at $3,648,000 after buying an additional 95,000 shares during the period. ProShare Advisors LLC boosted its position in shares of Cempra by 9.6% in the fourth quarter. ProShare Advisors LLC now owns 39,993 shares of the company’s stock valued at $1,245,000 after buying an additional 3,490 shares during the period. Gabelli Funds LLC boosted its position in shares of Cempra by 19.7% in the fourth quarter. Gabelli Funds LLC now owns 93,509 shares of the company’s stock valued at $2,911,000 after buying an additional 15,409 shares during the period. Finally, CAM Group Holding A S boosted its position in shares of Cempra by 2.6% in the fourth quarter. CAM Group Holding A S now owns 786,930 shares of the company’s stock valued at $24,497,000 after buying an additional 20,000 shares during the period.

Cempra Inc is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.